<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="232328">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052078</url>
  </required_header>
  <id_info>
    <org_study_id>U01MH064089</org_study_id>
    <secondary_id>DSIR 84-CTP</secondary_id>
    <nct_id>NCT00052078</nct_id>
  </id_info>
  <brief_title>Child and Adolescent Anxiety Disorders (CAMS)</brief_title>
  <official_title>Child/Adolescent Anxiety Multimodal Treatment Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Mental Health (NIMH)</source>
  <brief_summary>
    <textblock>
      This 9-month study will compare the effectiveness of the medication sertraline (ZoloftÂ®),
      cognitive-behavioral therapy, the combination of these treatments, and placebo for youth
      with anxiety disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anxiety disorders are among the most common conditions affecting children and adolescents.
      These disorders impair school, social, and family functioning. When left untreated, they
      also put children at risk for major depression and substance abuse in late adolescence and
      adulthood. Effective treatments that alleviate symptoms and prevent long-term morbidity and
      mortality associated with childhood-onset anxiety disorders are needed.

      During Phase I of this two-phase study, participants are randomly assigned to receive
      sertraline (Zoloft), cognitive behavioral therapy, a combination of these treatments, or a
      placebo for 12 weeks. Phase II involves a 6-month maintenance period for participants that
      respond to any of the three active treatments.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2003</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of clinically significant improvement as rated by blind evaluator</measure>
    <time_frame>Measured at Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety symptoms rated by self and parent</measure>
    <time_frame>Measured at Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">488</enrollment>
  <condition>Anxiety Disorders</condition>
  <condition>Social Phobia</condition>
  <condition>Generalized Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive sertraline for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive cognitive behavioral therapy for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a combination of sertraline and cognitive behavioral therapy for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Participants will take sertraline for 12 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy (CBT)</intervention_name>
    <description>Participants will receive CBT for 12 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will take placebo capsules for 12 weeks.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV criteria for separation anxiety disorder, social phobia, or generalized
             anxiety disorder

        Exclusion Criteria:

          -  Major neurological disorder or medical illness that would interfere with
             participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYSPI/Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh/WPIC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <lastchanged_date>October 20, 2008</lastchanged_date>
  <firstreceived_date>January 22, 2003</firstreceived_date>
  <responsible_party>
    <name_title>John T. Walkup, MD</name_title>
    <organization>Johns Hopkins University</organization>
  </responsible_party>
  <keyword>Phobic Disorders</keyword>
  <keyword>Anxiety, Separation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
